Ocufolin for Diabetic Retinopathy
Phase-Based Progress Estimates
Effectiveness
Safety
Diabetic Retinopathy+5 More
Ocufolin - DietarySupplementEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial will help researchers understand if these devices can be used to study different eye conditions and if Ocufolin can help improve vision.
Eligible Conditions
- Diabetic Retinopathy
- Presbyopia
- Dementia
- Multiple Sclerosis
- Myopia
- Dry Eye
Treatment Effectiveness
Effectiveness Progress
Other trials for Diabetic Retinopathy
Study Objectives
5 Primary · 2 Secondary · Reporting Duration: up to 2 years
up to 2 years
Conjunctival blood flow velocity by functional slit-lamp (FSLB)
Conjunctival vasculature by functional slit-lamp (FSLB)
Corneal epithelial thickness
Retinal blood flow velocity by retinal function imager (RFI)
Retinal microstructure using OCT.
Retinal vasculature by optical coherence tomography angiography (OCTA)
Tear film thickness
Trial Safety
Safety Progress
Other trials for Diabetic Retinopathy
Trial Design
2 Treatment Groups
Observational Phase Group
1 of 2
Interventional Phase - Ocufolin Group
1 of 2
Active Control
Experimental Treatment
5000 Total Participants · 2 Treatment Groups
Primary Treatment: Ocufolin · No Placebo Group · N/A
Interventional Phase - Ocufolin Group
DietarySupplement
Experimental Group · 1 Intervention: Ocufolin · Intervention Types: DietarySupplementObservational Phase GroupNoIntervention Group · 1 Intervention: Observational Phase Group · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ocufolin
2017
N/A
~30
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years
Who is running the clinical trial?
University of MiamiLead Sponsor
787 Previous Clinical Trials
379,271 Total Patients Enrolled
1 Trials studying Diabetic Retinopathy
3,000 Patients Enrolled for Diabetic Retinopathy
Jianhua Wang, MD, PhDPrincipal InvestigatorBascom Palmer Eye Institute, University of Miami, Miami, FL
4 Previous Clinical Trials
161 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You can keep the eye open for imaging.\n
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Florida | 100.0% |
How old are they?
| 18 - 65 | 100.0% |
What portion of applicants met pre-screening criteria?
| Did not meet criteria | 100.0% |
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments